SCHEMBL20255183

SCHEMBL20255183

CC(C)(C)OC(=O)N1CCN(c2ccc(N)nc2)C(=O)C(C)(C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.42
▸ NR1H2 P55055 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GPR119 Q8TDV5 3/20 0.39
▸ MAP4K4 O95819 1/20 0.38
▸ BACE1 P56817 2/20 0.38
▸ CTSD P07339 1/20 0.38
▸ CTSE P14091 1/20 0.38
▸ ALOX5AP P20292 1/20 0.38
▸ FEN1 P39748 1/20 0.38
▸ F13A1 P00488 1/20 0.37
▸ TGM2 P21980 1/20 0.37
▸ TGM1 P22735 1/20 0.37
▸ PTPN11 Q06124 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20037633 0.90 NR1H2 (0.42) USP30NR1H2MAPTSMN1; SMN2MEN1
SCHEMBL29741868 0.82 GPR119 (0.50) NR1H2MAPTSMN1; SMN2MEN1TSHR
SCHEMBL29491152 0.82 MAPT (0.44) NR1H2MAPTSMN1; SMN2MEN1TSHR
SCHEMBL255485 0.82 MAPT (0.44) NR1H2MAPTSMN1; SMN2MEN1TSHR
SCHEMBL18291496 0.81 USP30 (0.53) USP30MAPTSMN1; SMN2MEN1TSHR
SCHEMBL20037632 0.81 MAPT (0.43) NR1H2MAPTSMN1; SMN2MEN1TSHR
SCHEMBL1393764 0.79 MAPT (0.56) MAPTSMN1; SMN2MEN1TSHRKMT2A
SCHEMBL29426702 0.79 MAPT (0.56) MAPTSMN1; SMN2MEN1TSHRKMT2A
SCHEMBL2300710 0.79 HRH3 (0.54) USP30MAPTSMN1; SMN2MEN1TSHR
SCHEMBL18291718 0.78 LIPE (0.44) USP30MAPTSMN1; SMN2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 USP30 3352/4885NR1H2 3830/4885MAPT 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback